Skip to main content
. 2012 Apr 24;72(2):229–234. doi: 10.1136/annrheumdis-2011-201108

Table 4.

Incidence and HR of shingles

Result nbDMARD n=3673 All TNF n=11 881 Etanercept n=4139 Infliximab n=3475 Adalimumab n=4267
Follow-up (patient-years) 5417 17 048 6122 4529 6397
Shingles events 45 275 99 91 85
Shingles incidence (/100 patient-years) 0.8 (0.6–1.1) 1.6 (1.4–1.8) 1.6 (1.3–2.0) 2.0 (1.6–2.5) 1.3 (1.1–1.6)
Shingles unadjusted HR Ref 1.9 (1.4–2.6) 1.7 (1.2–2.5) 2.4 (1.7–3.4) 1.7 (1.2–2.5)
Shingles adjusted HR* Ref 1.7 (1.1–2.7) 1.7 (1.0–2.7) 2.2 (1.4–3.4) 1.5 (0.9–2.4)
*

Adjusted rates using propensity modelling described in the Methods section and using multiple imputations to replace missing baseline variables.

nbDMARD, non-biological disease-modifying antirheumatic drug; TNF, tumour necrosis factor.